Sun Pharmaceutical Industries Limited announced that UNLOXCYT® (cosibelimab-ipdl) has received a Category 2A Preferred Designation in the updated National Comprehensive Cancer Network (NCCN) Guidelines. This recommendation applies to patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.

The designation marks an expansion of the drug’s clinical standing, following its initial Category 2A assignment for metastatic cutaneous squamous cell carcinoma (mCSCC) in 2025. UNLOXCYT was approved by the U.S. Food and Drug Administration (FDA) in 2024 and remains the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC (aCSCC).

Clinical evidence and safety profile

The NCCN decision was supported by data from the pivotal registration study, which demonstrated significant efficacy and a manageable safety profile in this patient population. Key clinical outcomes included:

• Objective Response Rate: 55% of patients achieved an objective response, including 26% who achieved a complete response.
• Durability: At a median follow-up of 24.1 months, the median duration of response had not been reached, with responses ranging from 8.3 to over 31.3 months.
• Safety: Fewer than 1% of patients experienced high-grade (Grade 3-5) immune-mediated adverse reactions (imARs). No Grade 4 or 5 imARs were reported.

Dr. Francis Worden, Clinical Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, noted that the guideline update reflects the strength of published evidence supporting UNLOXCYT as a first-line treatment. He highlighted that the low incidence of high-grade imARs is critical for an elderly population often afflicted with comorbidities.

Impact on patient access

NCCN Guidelines significantly influence payer coverage policies, prior-authorization criteria, and institutional formularies. Ahmad Naim, Senior Vice President and North American Chief Medical Officer at Sun Pharma, stated that the elevation validates the growing body of clinical evidence and reflects increasing confidence among oncology experts.

Mark Gimbert, Senior Vice President and Head of Market and Patient Access at Sun Pharma, emphasized that NCCN recognition helps ensure appropriate patients receive treatment without unnecessary access barriers. This is particularly relevant for laCSCC patients, who are often older and medically complex.

What the numbers show

The dual approval for both metastatic and locally advanced settings positions UNLOXCYT as a comprehensive solution for advanced cutaneous squamous cell carcinoma. The consistent Category 2A status across both indications suggests robust expert consensus on its utility. Furthermore, the <1% rate of severe immune-mediated adverse reactions contrasts with typical profiles of other checkpoint inhibitors, potentially offering a distinct competitive advantage in tolerability for fragile patient cohorts.

Sun Pharmaceutical Industries has scheduled a board meeting on October 12, 2026, to consider a non-convertible debenture (NCD) issue of up to ₹15,000 crore through private placement.

Board meeting details

The following key details have been disclosed regarding the proposed fundraise:

The board will deliberate on the proposal to raise funds via listed and rated NCDs. This debt instrument is commonly used by corporates to access capital markets through a select group of investors rather than a public offering.

Regulatory disclosure

The company intimated the National Stock Exchange and BSE under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms the NCDs will be rated and redeemable, issued in one or more tranches for an aggregate amount not exceeding ₹15,000 crore.